ReviewDiagnostics (Basel, Switzerland)2025
Advanced Pulmonary Sarcoidosis: Treatment and Monitoring.
Review in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pulmonary sarcoidosis with pleural involvement in a 44-year-old patient: a case report.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoidosis is a multi-system inflammatory disease that poses several challenges to clinicians involved. Detecting advanced pulmonary sarcoidosis (APS) remains crucial at presentation as well as at every clinic visit since such a form of the disease is associated with an increased risk of developing respiratory failure, pulmonary hypertension (PH), and infectious complications, particularly in immunocompromised patients. As a result, APS accounts for the majority of sarcoidosis-related deaths. In this review, we focus on the definition of APS based on the identification of prognostic factors in pulmonary sarcoidosis. Additionally, we describe monitoring strategies for the detection of any disease progression and significant complications associated with the disease prognosis, such as pulmonary hypertension. Finally, the available treatment regimens for APS are reviewed with the aim of assessing the role of treatment strategies, especially since some patients are now eligible for antifibrotic treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.